Latest News and Press Releases

Press release – No. 8 / 2023 Zealand Pharma submits New Drug Application to US FDA for dasiglucagon in congenital hyperinsulinism Copenhagen, Denmark, June 30, 2023 – Zealand Pharma A/S...

Company announcement – No. 26 / 2023 Total number of shares and voting rights in Zealand Pharma at June 30, 2023 Copenhagen, Denmark, June 30, 2023 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL)...

Press release – No. 7 / 2023 Zealand Pharma Submits Marketing Authorization Application for Dasiglucagon for Treatment of Severe Hypoglycemia in Diabetes to the European Medicines Agency ...

Press release – No. 6 / 2023 Zealand Pharma Presents Results from Phase 1 Clinical Trial of Amylin Analog ZP8396 at ADA Scientific Sessions Body weight reductions reached up to a mean...

Press Release­­­­­­­ No. 5 / 2023 Data shows nearly 19% weight loss in people with overweight or obesity in Boehringer Ingelheim and Zealand Pharma Phase II trial with...

Company announcement – No. 25 / 2023 Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants Copenhagen, Denmark, June 8, 2023 – Zealand Pharma A/S (“Zealand”)...

Press release – No. 4 / 2023 Zealand Pharma to Participate in Upcoming Healthcare Conferences Copenhagen, Denmark, June 6, 2023 – Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (CVR-no. 20045078),...

Company announcement – No. 24 / 2023 Total number of shares and voting rights in Zealand Pharma at May 31, 2023 Copenhagen, Denmark, May 31, 2023 – Zealand Pharma A/S (“Zealand”)...

Company announcement – No. 23 / 2023 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons ...

Company announcement – No. 22 / 2023 Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants Copenhagen, Denmark, May 23, 2023 – Zealand Pharma A/S...